Pharmaceutical composition comprising low concentrations of environmental pollutants
The invention relates to a process for decreasing the amount of environmental pollutants in a mixture comprising a fat or an oil, being edible or for use in cosmetics, the fat or oil containing the environmental pollutants, which process comprises the steps of adding a volatile working fluid to the mixture, where the volatile working fluid comprises at least one of a fatty acid ester, a fatty acid amide, a free fatty acid and a hydro-carbon, and subjecting the mixture with the added volatile working fluid to at least one stripping processing step, in which an amount of environmental pollutant present in the fat or oil, being edible or for use in cosmetics, is separated from the mixture together with the volatile working fluid. The present invention also relates to a volatile environmental pollutants decreasing working fluid, for use in decreasing an amount of environmental pollutants present in a fat or oil, being edible or for use in cosmetics. In addition, the present invention relates to a health supplement, a pharmaceutical and an animal feed product prepared according to the process mentioned above.
1. A pharmaceutical composition comprising a marine oil which comprises eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester in a pharmaceutically effective concentration to therapeutically treat hypertriglyceridaemia,
wherein the concentration of brominated flame retardants in the pharmaceutical composition is less than 0.2 μg/kg as measured by the concentration of BDE 47, and
wherein said pharmaceutical composition is not a health supplement.
2. A pharmaceutical composition according to claim 1 , further wherein the sum of PCDDs and PCDFs in the marine oil is less than 4.65 pg/g.
3. A pharmaceutical composition according to claim 1 , further wherein the sum of TE-PCBs in the marine oil is less than 22.6 pg/g.
4. A pharmaceutical composition comprising a marine oil which comprises eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester in a pharmaceutically effective concentration to therapeutically treat hypertriglyceridaemia,
wherein the sum of TE-PCB in the marine oil is less than 22.6 pg/g, and
wherein said pharmaceutical composition is not a health supplement.
5. A pharmaceutical composition prepared from a marine oil, wherein the pharmaceutical composition is prepared by
reducing the concentration of brominated flame retardants as measured by the concentration of BDE 47 in the marine oil, and
increasing the concentration of eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester in the marine oil to a pharmaceutically effective concentration to therapeutically treat hypertriglyceridaemia, and
wherein said pharmaceutical composition is not a health supplement.
6. A pharmaceutical composition according to claim 5 , wherein the concentration of brominated flame retardants in the pharmaceutical composition is less than 0.2 μg/kg as measured by the concentration of BDE 47.
7. A pharmaceutical composition prepared from a marine oil, wherein the pharmaceutical composition is prepared by
reducing the sum of TE-PCB as measured in the marine oil, and
increasing the concentration of eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester in the marine oil to a pharmaceutically effective concentration to therapeutically treat hypertriglyceridaemia, and
wherein said pharmaceutical composition is not a health supplement.
8. A pharmaceutical composition according to claim 7 , wherein the sum of TE-PCB in the marine oil is less than 22.6 pg/g.
9. A method of treating at least one cardiovascular disease comprising administering a pharmaceutical composition comprising a marine oil which comprises eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester in a pharmaceutically effective concentration to therapeutically treat hypertriglyceridaemia,
wherein the concentration of brominated flame retardants in the pharmaceutical composition is less than 0.2 μg/kg as measured by the concentration of BDE 47, and
wherein said pharmaceutical composition is not a health supplement.
10. A method according to claim 9 , wherein the at least one cardiovascular disease is hypertriglyceridaemia.
11. A method according to claim 10 , further wherein the sum of TE-PCB in the marine oil is less than 22.6 pg/g.
12. A pharmaceutical composition comprising a marine oil which comprises eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester in a pharmaceutically effective concentration to therapeutically treat hypertriglyceridaemia,
wherein the concentration of BDE 47 in the marine oil is less than 12.2 ng/g, and
wherein said pharmaceutical composition is not a health supplement.
13. A pharmaceutical composition according to claim 4 , wherein the concentration of BDE 47 in the marine oil is less than 12.2 ng/g.
14. A pharmaceutical composition according to claim 5 , wherein the concentration of BDE 47 is less than 12.2 ng/g in the marine oil after reducing the concentration of brominated flame retardants as measured by the concentration of BDE 47 in the marine oil.
15. A pharmaceutical composition according to claim 1 , further wherein the sum of PCDDs and PCDFs in the marine oil is 0.46 pg/g or between 0.46 pg/g and 4.65 pg/g.
16. A pharmaceutical composition according to claim 4 , further wherein the sum of TE-PCB in the marine oil is 0.09 pg/g or between 0.09 pg/g and 22.6 pg/g.
17. A pharmaceutical composition according to claim 12 , further wherein the concentration of BDE 47 in the marine oil is less than 5.3 μg/kg.